Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases | Zendy

Louis S. Matza | Zendy; Cong Cong | Zendy; Chung | Zendy; Alison Stopeck | Zendy; Katia Tonkin | Zendy; Brown | Zendy; Браун | Zendy; Van Brunt | Zendy; Kelly McDaniel | Zendy

Open Access

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

Author(s) -

Louis S. Matza,

Cong Cong,

Chung,

Alison Stopeck,

Katia Tonkin,

Brown,

Браун,

Van Brunt,

Kelly McDaniel

Publication year - 2013

Publication title -

patient preference and adherence

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.885

H-Index - 48

ISSN - 1177-889X

DOI - 10.2147/ppa.s44947

Subject(s) - medicine , intravenous infusions , subcutaneous injection , intravenous fluid , intensive care medicine , anesthesia

Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research